New insights into the optimal management of COPD: extracts from CHEST 2021 annual meeting (October 17–20, 2021)

References

• World Health Organization. The top 10 causes of death 2018 [cited 2021 Jul 7]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2019 report) 2019. [cited 2021 Jul 7]. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf
   Google Scholar
• World Health Organization. COPD management 2016 [cited 2021 Jul 7]. Available from: https://www.who.int/respiratory/copd/management/en/
   Google Scholar
• Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014 Mar;35(1):157–163. PubMed PMID: 24507843.
   PubMed Web of Science ®Google Scholar
• Press VG, Konetzka RT, White SR. Insights about the economic impact of chronic obstructive pulmonary disease readmissions post implementation of the hospital readmission reduction program. Curr Opin Pulm Med. 2018 Mar;24(2):138–146. PubMed PMID: 29210750; PubMed Central PMCID: PMCPMC5810972. eng.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report) 2020. [updated 2020 Nov 25]; [cited 2021 April 14]. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management and prevention - A guide for health care professionals (2021 report) 2020 [cited 2021 Aug 5]. Available from 2021 Aug 5: https://goldcopd.org/wp-content/uploads/2020/12/GOLD-2021-POCKET-GUIDE-v2.0-14Dec20_WMV.pdf
   Google Scholar
• Arnold MJ. Treatment of chronic obstructive pulmonary disease: guidelines from the American Thoracic Society. Am Fam Physician. 2021 Jul 1;104(1):102–103. PubMed PMID: 34264596.
   PubMed Web of Science ®Google Scholar
• White P, Thornton H, Pinnock H, et al. Overtreatment of COPD with inhaled corticosteroids–implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221. PubMed PMID: 24194824; PubMed Central PMCID: PMCPMC3806778.
   PubMed Web of Science ®Google Scholar
• Make B, Dutro MP, Paulose-Ram R, et al. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis. 2012;7:1–9. PubMed PMID: 22315517; PubMed Central PMCID: PMCPMC3273365. eng.
   PubMed Web of Science ®Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020 May 1;201(9):e56–e69. PubMed PMID: 32283960; PubMed Central PMCID: PMCPMC7193862.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508–1516. PubMed PMID: 32162970; PubMed Central PMCID: PMCPMC7301738.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018 May 3;378(18):1671–1680. PubMed PMID: 29668352.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020 Jul 2;383(1):35–48. PubMed PMID: 32579807.
   PubMed Web of Science ®Google Scholar
• Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. Eur Respir J. 2018 Dec;52(6):1801848. PubMed PMID: 30545959.
   PubMed Web of Science ®Google Scholar
• Suissa S. Perplexing mortality data from triple therapy trials in COPD. Lancet Respir Med. 2021 Jul;9(7):684–685. PubMed PMID: 34126054; eng.
   PubMed Web of Science ®Google Scholar
• Suissa S. Triple therapy in COPD: time for adaptive selection trials. COPD. 2021;1–5. DOI:https://doi.org/10.1080/15412555.2021.1982886
   Google Scholar
• Halpin DM, Kerkhof M, Soriano JB, et al. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir Res. 2016 Sep 23;17(1):120. PubMed PMID: 27663386; PubMed Central PMCID: PMCPMC5034631.
   PubMedGoogle Scholar
• Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626.
   PubMed Web of Science ®Google Scholar
• Cabrera C, Quélen C, Ouwens M, et al. Evaluating a Cox marginal structural model to assess the comparative effectiveness of inhaled corticosteroids versus no inhaled corticosteroid treatment in chronic obstructive pulmonary disease. Ann Epidemiol. 2021 Nov;67:19–28. PubMed PMID: 34798296; eng.
   PubMedGoogle Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice. Chest. 2020 Apr;157(4):846–855. PubMed PMID: 31759966; eng.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on mortality. COPD. 2021;1–9. DOI:https://doi.org/10.1080/15412555.2021.1977789
   Google Scholar
• Souliotis K, Silva Miguel L, Hillas G, et al. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926802. PubMed PMID: 32519591; PubMed Central PMCID: PMCPMC7288795. eng.
   Web of Science ®Google Scholar
• Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018 Dec;52(6):1801219. PubMed PMID: 30190269.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Strange C. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Int J Chron Obstruct Pulmon Dis. 2018;13:2587–2601. PubMed PMID: 30214177; PubMed Central PMCID: PMCPMC6118265. eng.
   PubMed Web of Science ®Google Scholar
• Palli S, Zhou S, Shaikh A, et al. Real-world impact of GOLD compliant COPD maintenance therapy on exacerbations and treatment patterns. Poster presented at: CHEST Annual Meeting; 2021 Oct 17-20; Orlando, Florida.
   Google Scholar
• Palli S, Zhou S, Shaikh A, et al. Developing a claims’-based algorithm to identify US patients with COPD. Eur Respir J. 2019;54(Suppl 63):A4431.
   Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017 Mar 1;195(5):557–582. PubMed PMID: 28128970.
   PubMed Web of Science ®Google Scholar
• Quint JK, Montonen J, He X, et al. Effectiveness of COPD maintenance therapy with a LAMA/LABA versus LAMA/LABA/inhaled corticosteroids in a US claims database. Poster presented at: CHEST Annual Meeting; 2021 Oct 17-20; Orlando, Florida.
   Google Scholar
• Palli S, Anderson AJ, Le L, et al. Annual expenditures among patients with COPD initiating tiotropium/olodaterol versus triple therapy. Poster presented at: CHEST Annual Meeting; 2021 Oct 17-20; Orlando, Florida.
   Google Scholar
• Wachtel H, Jugovic B, Singh D. An investigation of factors affecting inhalation profiles of COPD patients. Paper presented at: CHEST Annual Meeting; 2021 Oct 17-20; Orlando, Florida.
   Google Scholar
• Mahler DA, Ludwig-Sengpiel A, Ferguson GT, et al. TRONARTO: a randomized, placebo-controlled study of tiotropium/olodaterol delivered via soft mist inhaler in COPD patients stratified by peak inspiratory flow. Int J Chron Obstruct Pulmon Dis. 2021;16:2455–2465. PubMed PMID: 34511891; PubMed Central PMCID: PMCPMC8414074. eng.
   PubMed Web of Science ®Google Scholar
• Giessel GM, Attick S, Franceschina J, et al. New paradigms in clinical study design: patient and sponsor perspectives from a fully remote study utilizing digital technologies. Paper presented at: CHEST Annual Meeting; 2021 Oct 17-20; Orlando, Florida.
   Google Scholar
• ClinicalTrials.gov. The ENERGITO® 2 study compares 2 inhaled medicines for chronic obstructive pulmonary disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus (NCT03240575).
   Google Scholar
• Wise R, Abrahams R, Westerman JH, et al. The lung function profile of patients with COPD receiving once-daily tiotropium/olodaterol versus twice-daily fluticasone propionate/salmeterol in ENERGITO 2 clinical trial. J Precis Respir Med. 2019;2(1):57–66.
   Google Scholar